GU Qin , LI Yan-Ping , WU Sai-Qi , ZHANG Yu-Yang , LI Jiang . Relationship of Estrogen and its Receptors and Risk of Thyroid Cancer[J]. Chinese Journal of Clinical Anatomy, 2014 , 32(6) : 747 -749 . DOI: 10.13418/j.issn.1001-165x.2014

[1]  Howlader N, Noone AM, Yu M, et al. Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer
[J]. Am J Epidemiol,2012,176(4):347-356.

[2]  Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005
[J]. Cancer Epidemiol Biomarkers Prev,2009,18(3):784-791.

[3]  Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity
[J]. Future Oncol,2010,6(11):1771-1779.

[4]  Revankar C M, Cimino D F, Sklar L A, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling
[J]. Science,2005,307(5715):1625-1630.

[5]  Chen G G, Zeng Q, Tse G M. Estrogen and its receptors in cancer
[J]. Med Res Rev,2008,28(6):954-974.

[6]  Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets
[J]. Physiol Rev,2007,87(3):905-931.

[7]  Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic  actions on target genes
[J]. Mol Endocrinol,2005,19(4):833-842.

[8]  Kawabata W, Suzuki T, Moriya T, et al. Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type  1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions
[J]. Mod Pathol,2003,16(5):437-444.

[9]  Vaiman M, Olevson Y, Habler L, et al. The estrogen receptors in the papillary carcinoma of the thyroid gland
[J]. Oncol Res,2010,18(11-12):537-540.

[10] Vaiman M, Olevson Y, Sandbank J, et al. Are estrogen receptors alpha detectable in normal and abnormal thyroid tissue
[J] ? Eur Arch Otorhinolaryngol,2010,267(11):1753-1757.

[11] Hiasa Y, Nishioka H, Kitahori Y, et al. Immunohistochemical analysis of estrogen receptors in 313 paraffin section cases  of human thyroid tissue
[J]. Oncology,1993,50(2):132-136.

[12] Di Vito M, De Santis E, Perrone G A, et al. Overexpression of estrogen receptor-alpha in human papillary thyroid carcinomas studied by laser- capture microdissection and molecular biology
[J]. Cancer Sci,2011,102(10):1921-1927.

[13] Zeng Q, Chen G G, Vlantis A C, et al. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway
[J]. Cell Prolif,2007,40(6):921-935.

[14] Cho M A, Lee M K, Nam K H, et al. Expression and role of estrogen receptor alpha and beta in medullary thyroid carcinoma: different roles in cancer growth and apoptosis
[J]. J Endocrinol, 2007,195(2):255-263.

[15]Vivacqua A, Bonofiglio D, Albanito L, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30
[J]. Mol Pharmacol,2006,70(4):1414-1423.

[16] Furlanetto T W, Nguyen L Q, Jameson J L. Estradiol increases proliferation and down-regulates the sodium/iodide symporter  gene in FRTL-5 cells
[J]. Endocrinology,1999,140(12):5705-5711.

[17] Manole D, Schildknecht B, Gosnell B, et al. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms
[J]. J ClinEndocrinol Metab, 2001,86(3):1072-1077.

[18] Rajoria S, Suriano R, Shanmugam A, et al. Metastatic phenotype is regulated by estrogen in thyroid cells
[J]. Thyroid, 2010, 20(1):33-41.

[19] Roudabush FL, Pierce KL, Maudsley S, et al. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells
[J]. J Biol Chem, 2000, 275(29):22583-22589.

[20] Song RX, Zhang Z, Chen Y, et al. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells
[J]. Endocrinology, 2007,148(8):4091-4101.

[21] Rajoria S, Suriano R, George A, et al. Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer
[J]. PLoS One,2011,6(1):e15879.

[22] Yeh MW, Rougier JP, Park JW, et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A
[J]. EndocrRelat Cancer, 2006, 13(4):1173-1183.

[23] Tian X, Cong M, Zhou W, et al. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer
[J]. J Int Med Res, 2008,36(4):699-703.

[24] Losordo DW, Isner JM. Estrogen and angiogenesis: A review
[J]. ArteriosclerThrombVasc Biol, 2001,21(1):6-12.

[25] Ucuzian AA, Gassman AA, East AT, et al. Molecular mediators of angiogenesis
[J]. J Burn Care Res, 2010, 31(1):158-175.

[26] Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid
[J]. J ClinEndocrinol Metab,1997,82(11):3741-3747.

[27] Kamat A, Rajoria S, George A, et al. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways
[J]. Arch Otolaryngol Head Neck Surg, 2011,137(11):1146-1153.

[28] Fink K, Boratynski J. The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis
[J]. PostepyHig Med Dosw (Online),2012,66:609-628.